Literature DB >> 32822771

Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations.

Gary Gintant1, Emily Pfeiffer Kaushik2, Tromondae Feaster3, Sonja Stoelzle-Feix4, Yasunari Kanda5, Tomoharu Osada6, Godfrey Smith7, Katherine Czysz8, Ralf Kettenhofen9, Hua Rong Lu10, Beibei Cai11, Hong Shi12, Todd Joseph Herron13, Qianyu Dang14, Francis Burton15, Li Pang16, Martin Traebert17, Yama Abassi18, Jennifer Beck Pierson19, Ksenia Blinova20.   

Abstract

Human stem cell-derived cardiomyocytes (hSC-CMs) hold great promise as in vitro models to study the electrophysiological effects of novel drug candidates on human ventricular repolarization. Two recent large validation studies have demonstrated the ability of hSC-CMs to detect drug-induced delayed repolarization and "cellrhythmias" (interrupted repolarization or irregular spontaneous beating of myocytes) linked to Torsade-de-Pointes proarrhythmic risk. These (and other) studies have also revealed variability of electrophysiological responses attributable to differences in experimental approaches and experimenter, protocols, technology platforms used, and pharmacologic sensitivity of different human-derived models. Thus, when evaluating drug-induced repolarization effects, there is a need to consider 1) the advantages and disadvantages of different approaches, 2) the need for robust functional characterization of hSC-CM preparations to define "fit for purpose" applications, and 3) adopting standardized best practices to guide future studies with evolving hSC-CM preparations. Examples provided and suggested best practices are instructional in defining consistent, reproducible, and interpretable "fit for purpose" hSC-CM-based applications. Implementation of best practices should enhance the clinical translation of hSC-CM-based cell and tissue preparations in drug safety evaluations and support their growing role in regulatory filings.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiotoxicity; Cardiovascular safety assessment; Cellrhythmias; CiPA; Delayed repolarization; JiCSA; Nonclinical safety; Proarrhythmic risk assessment; Safety pharmacology; hSC-CM

Mesh:

Substances:

Year:  2020        PMID: 32822771     DOI: 10.1016/j.yrtph.2020.104756

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  5 in total

1.  A multiscale approach for bridging the gap between potency, efficacy, and safety of small molecules directed at membrane proteins.

Authors:  Rodrigo Aguayo-Ortiz; Jeffery Creech; Eric N Jiménez-Vázquez; Guadalupe Guerrero-Serna; Nulang Wang; Andre Monteiro da Rocha; Todd J Herron; L Michel Espinoza-Fonseca
Journal:  Sci Rep       Date:  2021-08-16       Impact factor: 4.379

Review 2.  Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).

Authors:  David G Strauss; Wendy W Wu; Zhihua Li; John Koerner; Christine Garnett
Journal:  Clin Pharmacol Ther       Date:  2021-01-07       Impact factor: 6.875

3.  Role of the rapid delayed rectifier K+ current in human induced pluripotent stem cells derived cardiomyocytes.

Authors:  Makarand Deo; Akwasi Akwaboah; Bright Tsevi; Jacqueline A Treat; Jonathan M Cordeiro
Journal:  Arch Stem Cell Ther       Date:  2020

4.  Cardiac Safety of Kinase Inhibitors - Improving Understanding and Prediction of Liabilities in Drug Discovery Using Human Stem Cell-Derived Models.

Authors:  Ricarda Ziegler; Fabian Häusermann; Stephan Kirchner; Liudmila Polonchuk
Journal:  Front Cardiovasc Med       Date:  2021-06-16

5.  Acute effects of cardiac contractility modulation on human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Tromondae K Feaster; Maura Casciola; Akshay Narkar; Ksenia Blinova
Journal:  Physiol Rep       Date:  2021-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.